Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMMDQ5T)

Drug Name
ZK-93426 Drug Info
Synonyms
ZK-93426; ZK 93426; ZK93426; ZK 93 426; CHEMBL1271047; 89592-45-0; 5-Isopropoxy-4-methyl-beta-carboline-3-carboxylic acid ethyl ester; Ethyl 4-methyl-5-(1-methylethoxy)-9H-pyrido(3,4-b)indole-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-methyl-5-(1-methylethoxy)-, ethyl ester; AC1L3GQB; SCHEMBL195334; GTPL4347; CHEBI:93201; ZINC5857864; BDBM50329658; NCGC00161396-01; LS-178094; BRD-K68392338-003-01-2; ethyl 5-isopropoxy-4-methyl-9H-pyrido[3,4-b]indole-3-carboxylate; ethyl 4-methyl-5-propan-2-yloxy-9H-pyrido[5,4-
Cross-matching ID
PubChem CID
115210
ChEBI ID
CHEMBL1271047
CAS Number
CAS 89592-45-0
TTD Drug ID
D0P3IE

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mineral absorption 2.20 0.00e+0 48/60 (80%) TF;SLC26A3;MT1F;...
Retinol metabolism 1.78 4.69e-2 41/68 (60.29%) UGT2B17;ADH5;UGT2B15;...
Drug metabolism 1.77 3.52e-2 78/151 (51.66%) UGT2B17;ADH5;UGT2B15;...
RNA degradation 1.75 3.44e-2 53/79 (67.09%) CNOT4;LSM5;PABPC3;...
Porphyrin and chlorophyll metabolism 1.71 4.82e-2 23/43 (53.49%) UGT2B17;UGT2B15;UGT2B28;...
Citrate cycle (TCA cycle) -1.62 4.35e-2 30/30 (100%) DLST;IDH3A;DLD;...
Biosynthesis of unsaturated fatty acids -1.62 4.45e-2 21/27 (77.78%) ACOX1;SCD;ACAA1;...
Fc epsilon RI signaling pathway -1.65 3.84e-2 57/68 (83.82%) IL4;KRAS;MAP2K3;...
Endocytosis -1.68 2.73e-2 198/252 (78.57%) ARAP3;CXCR2;PML;...
Synaptic vesicle cycle -1.68 2.83e-2 63/78 (80.77%) SLC18A2;DNM3;SLC17A6;...
Cell adhesion molecules -1.69 2.66e-2 118/148 (79.73%) ICOS;CD58;NLGN1;...
Tryptophan metabolism -1.69 2.72e-2 35/42 (83.33%) DLST;DLD;KYAT3;...
Propanoate metabolism -1.70 2.73e-2 30/34 (88.24%) ECHS1;ACOX1;ACADS;...
Th1 and Th2 cell differentiation -1.71 2.41e-2 80/92 (86.96%) RELA;IL13;IL5;...
beta-Alanine metabolism -1.72 2.41e-2 25/30 (83.33%) ALDH3A1;ECHS1;ACOX1;...
Natural killer cell mediated cytotoxicity -1.77 1.51e-2 99/131 (75.57%) MAP2K1;ARAF;PIK3R1;...
Autophagy -1.80 1.08e-2 113/169 (66.86%) TSC1;STK11;PPP2CA;...
Valine, leucine and isoleucine degradation -1.82 7.38e-3 42/48 (87.5%) HADHB;MCCC1;HMGCL;...
Glyoxylate and dicarboxylate metabolism -1.82 7.81e-3 23/30 (76.67%) ACAT2;CAT;AMT;...
Lysosome -1.83 8.30e-3 115/128 (89.84%) NAGA;CTSH;AP1S2;...
Tuberculosis -1.84 7.24e-3 159/180 (88.33%) TNFRSF1A;PIK3C3;NFYA;...
Toxoplasmosis -1.87 6.90e-3 103/112 (91.96%) ITGB1;AKT1;BAD;...
Osteoclast differentiation -1.87 7.43e-3 117/127 (92.13%) STAT2;PIK3R3;TYK2;...
Type I diabetes mellitus -1.89 7.04e-3 38/43 (88.37%) LTA;FAS;HLA-DRB1;...
Hematopoietic cell lineage -1.93 5.49e-3 90/99 (90.91%) CD55;EPOR;ITGA1;...
Viral myocarditis -1.96 2.41e-3 53/60 (88.33%) SGCD;CD55;FYN;...
Rheumatoid arthritis -2.00 1.34e-3 78/93 (83.87%) HLA-DRB1;TCIRG1;ATP6V1E1;...
Autoimmune thyroid disease -2.02 1.51e-3 46/53 (86.79%) FAS;HLA-DRB1;HLA-G;...
Leishmaniasis -2.04 1.72e-3 67/77 (87.01%) ITGB1;CR1;HLA-DRB1;...
Steroid biosynthesis -2.13 0.00e+0 19/20 (95%) FDFT1;SOAT1;MSMO1;...
Mitophagy -2.18 0.00e+0 56/68 (82.35%) MAPK10;NBR1;BCL2L13;...
Phagosome -2.18 0.00e+0 118/152 (77.63%) THBS4;PIKFYVE;HLA-DRB1;...
Antigen processing and presentation -2.23 0.00e+0 60/78 (76.92%) CD4;CD8A;NFYA;...
Graft-versus-host disease -2.26 0.00e+0 32/42 (76.19%) FAS;HLA-DRB1;HLA-G;...
Allograft rejection -2.29 0.00e+0 32/38 (84.21%) FAS;HLA-DRB1;HLA-G;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H